{"id":7518,"date":"2025-09-22T12:30:49","date_gmt":"2025-09-22T10:30:49","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=7518"},"modified":"2025-09-22T12:30:49","modified_gmt":"2025-09-22T10:30:49","slug":"efficacy-of-zanubrutinib-versus-acalabrutinib-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/efficacy-of-zanubrutinib-versus-acalabrutinib-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-a-matching-adjusted-indirect-comparison\/","title":{"rendered":"Efficacy of Zanubrutinib Versus Acalabrutinib for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison"},"content":{"rendered":"","protected":false},"template":"","post-tag":[559,613,612,629,673,628,594,656,635,626,542],"class_list":["post-7518","publication","type-publication","status-publish","hentry","post-tag-alpine","post-tag-brutons-tyrosine-kinase","post-tag-brutons-tyrosine-kinase-inhibitor","post-tag-btk","post-tag-btk-inhibitor","post-tag-btki","post-tag-chronic-lymphocytic-leukemia","post-tag-cll","post-tag-maic","post-tag-matching-adjusted-indirect-comparison","post-tag-zanubrutinib","disease_state-chronic-lymphocytic-leukemia","molecule-zanubrutinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/7518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7518"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}